Company Description
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress.
The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.
It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea.
The company is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Lisa Conte |
Contact Details
Address: 200 Pine Street, Suite 400 San Francisco, California 94104 United States | |
| Phone | 415 371 8300 |
| Website | jaguar.health |
Stock Details
| Ticker Symbol | JAGX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001585608 |
| CUSIP Number | 47010C888 |
| ISIN Number | US47010C8881 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Lisa A. Conte | Founder, Chief Executive Officer, President and Director |
| Dr. Pravin R. Chaturvedi Ph.D. | Chief Scientific Officer and Chair of Scientific Advisory Board |
| Jonathan S. Wolin CPA, J.D., M.B.A. | Chief of Staff, Chief Compliance Officer and General Counsel |
| Dr. Steven R. King Ph.D. | Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary |
| Carol R. Lizak M.B.A. | Chief Financial Officer and Chief Accounting Officer |
| Peter Hodge | Senior Director of Investor Relations, Business Development and Special Events |
| Dr. Karen J. Brunke Ph.D. | Executive Vice President of Corporate and Business Development |
| David Sesin Ph.D. | Chief Manufacturing Officer |
| Ian H. Wendt M.B.A. | Chief Commercial Officer |
| Dr. Massimo Radaelli M.B.A., Ph.D. | President of Jaguar International |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 21, 2025 | ARS | Filing |
| Jul 21, 2025 | DEF 14A | Other definitive proxy statements |
| Jul 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Jun 30, 2025 | 8-K | Current Report |
| Jun 27, 2025 | EFFECT | Notice of Effectiveness |
| Jun 27, 2025 | 424B3 | Prospectus |
| Jun 27, 2025 | 424B5 | Filing |
| Jun 24, 2025 | 8-K | Current Report |
| Jun 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| May 28, 2025 | D | Notice of Exempt Offering of Securities |